# A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

> **NCT05995782** · PHASE1 · RECRUITING · sponsor: **1ST Biotherapeutics, Inc.** · enrollment: 64 (estimated)

## Conditions studied

- Parkinson Disease Psychosis
- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** FB418

## Key facts

- **NCT ID:** NCT05995782
- **Lead sponsor:** 1ST Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05995782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05995782, "A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05995782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*